- 英文名称
- (4R,4aS)-rel-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-24H,26H-Benzo[b]porphine-9,13-dipropanoic acid monomethyl ester
- 分子式
- C41H42N4O8
- 分子量
- 718.79
- 中文别名
- 维替泊芬; trans-3,4-Dicarboxy-4,4a-dihydro-4a,8,14,19-tetramethyl-18-vinyl-23H,25H-benzo(b)porphine-9,13-dipropionic acid 3,4,9-trimethyl ester; Visudyne; ,3(28),4,6,8,10,12,14,16(26),17,19,21-dodécaén-9-yl]propanoïque - acide 3-[(1Z,6Z,12Z,17Z,23S,24R)-14-éthényl-22,23-bis(méthoxycarbonyl)-9-(3-méthoxy-3-oxopropyl)-4,10,15,24-tétraméthyl-25,26,27,28-té; VERTEPORFIN (200 MG); trans-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropionic Acid Monomethyl Ester; ,4,6,8,10,12,14,16(26),17,19,21-dodecaen-9-yl]propanoic acid - 3-[(1Z,6Z,12Z,17Z,23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahex; ,4,6,8,10,12,14,16(26),17,19,21-dodecaen-9-yl]propansäure--3-[(1Z,6Z,12Z,17Z,23S,24R)-14-ethenyl-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyc; Verteporphin; 3-[(1Z,6Z,12Z,17Z,23S,24R)-22,23-Bis(methoxycarbonyl)-5-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-14-vinyl-25,26,27,28-tetraazahexacyclo[16.6.1.1.1.1.0]octacosa-1,3(28),4 ,6,8,10,12,14,16(26),17,19,21-dodecaen-9-yl]propanoic acid - 3-[(1Z,6Z,12Z,17Z,23S,24R)-22,23-bis(methoxycarbonyl)-9-(3-methoxy-3-oxopropyl)-4,10,15,24-tetramethyl-14-vinyl-25,26,27,28-tetraazahexacyc lo[16.6.1.1.1.1.0]o; Verteprofin
- 用途
- 维替泊芬为第二代卟啉类光敏剂，可被光(波长689nm)照射激活，用于光动力学疗法治疗黄斑退化。药物选择性进入不正常血管，光激活后产生活性氧闭塞血管，终止渗漏，保存视力。适用于继发于年龄相关性黄斑变性、病理性近视或可疑眼组织胞浆菌病的典型性为主型中心凹下脉络膜新生血管形成患者。静脉给药，分两步：①静注：无菌注射用水配制成2mg/mL注射液，6mg/m²体表面积，5% GS稀释为30mL，3mL/min注射10分钟，4小时内使用；②15分钟后用波长689±3nm激光照射病灶，剂量50J/cm²，强度600mW/cm²，83秒内完成。
